The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 311.00
High: 314.00
Low: 303.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Jul 2020 08:00

RNS Number : 2351S
Hutchison China Meditech Limited
07 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft

Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

 

Hutchison China MediTech Limited

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

General Atlantic Singapore HCM Pte. Ltd.

City and country of registered office (if applicable)

Singapore

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

06/07/2020

6. Date on which issuer notified (DD/MM/YYYY):

06/07/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial in- struments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which

threshold was crossed or reached

 

2.81%

 

2.35%

 

5.16%

 

710,574,765

Position of previous notification (if applicable)

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or

reachedviii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares KYG4672N1198

20,000,000

2.81%

SUBTOTAL 8. A

20,000,000

2.81%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

 

Type of financial instrument

 

Expiration datex

 

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

 

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration datex

Exercise/ Conversion Period xi

Physical or cash settlementxii

Number of voting rights

 

% of voting rights

Warrants over

Ordinary Shares

January 3,

2022

At any time after July 2,

2020

Physical

16,666,670

2.35%

SUBTOTAL 8.B.2

16,666,670

2.35%

 

 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

X

 

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial in- struments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

GAP (Bermuda) Limited

5.16%

General Atlantic LLC

5.16%

General Atlantic GenPar (Bermuda), L.P.

 

5.16%

General Atlantic (Lux) S.à r.l.

5.16%

General Atlantic GenPar (Lux) SCSp, L.P.

 

5.16%

General Atlantic Part- ners (Bermuda) IV, L.P.

 

5.16%

General Atlantic Part- ners (Bermuda) EU, L.P.

 

5.16%

General Atlantic Part- ners (Lux) SCSp, L.P.

 

5.16%

GAP Coinvestments III, LLC

 

5.16%

GAP Coinvestments IV, LLC

 

5.16%

GAP Coinvestments V, LLC

 

5.16%

GAP Coinvestments CDA, L.P.

 

5.16%

General Atlantic Singa- pore Interholdco Ltd.

 

5.16%

 

 

General Atlantic Singa- pore Fund Pte. Ltd.

 

5.16%

General Atlantic Singa- pore HCM Pte. Ltd.

5.16%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

 

 

 

11. Additional informationxvi

The warrants in Box B 2 have not been exercised, in part or whole, as of the below "Date of completion." Accordingly, the "Total number of voting rights of issuer" in Box 7 do not account for any issuance of the new voting shares, in part or whole, from the exercise of the warrants.

Once the warrants are exercised in full, assuming no other changes in the interests or the voting shares in the meantime, the "Total number of voting rights of issuer" in Box 7 will become 727,241,435. On that

basis, the ownership ordinary shares would represent 2.75%, the ownership of warrants would represent 2.29%, and the combined ownership of the ordinary shares and warrants would represent 5.04%.

 

 

Place of completion

Hong Kong, China

Date of completion

July 6, 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUBSNRRKUBRRR
Date   Source Headline
16th Jul 202110:50 amRNSHolding(s) in Company
16th Jul 20217:00 amRNSSurufatinib MAA Submitted and Validated by the EMA
14th Jul 20219:35 amRNSHolding(s) in Company
13th Jul 20217:00 amRNSFirst Commercial Sale of ORPATHYS® in China
12th Jul 20212:35 pmRNSFull Exercise of the Over-allotment Option
6th Jul 20219:30 amRNSHUTCHMED Initiates Phase I Trials of HMPL-295
2nd Jul 202111:15 amRNSHolding(s) in Company
2nd Jul 20219:30 amRNSNotice of Results
1st Jul 202111:00 amRNSUS FDA Accepts NDA Filing for Surufatinib
30th Jun 202110:02 amRNSHoldings in Company
30th Jun 202110:01 amRNSTotal Voting Rights
30th Jun 202110:00 amRNSClosing of Global Offering and Hong Kong Listing
29th Jun 20217:00 amRNSBlocklisting Six Monthly Return
23rd Jun 20213:21 pmRNSHUTCHMED Announces Pricing of Global Offering
22nd Jun 20216:22 pmRNSSavolitinib approved in China for lung cancer
18th Jun 20214:05 pmRNSHUTCHMED Announces NMPA Approval of Surufatinib
18th Jun 20217:01 amRNSHUTCHMED Launches Hong Kong IPO
18th Jun 20217:00 amRNSDisclosure Update
20th May 20217:00 amRNSClinical Data to be Presented at ASCO21
17th May 20217:00 amRNSHUTCHMED to Host Company Update
7th May 202112:00 pmRNSHUTCHMED to Attend Upcoming Investor Conferences
4th May 20218:00 amRNSChange of Company Name
4th May 20217:00 amRNSSurufatinib FDA Rolling NDA Submission Completed
30th Apr 20214:41 pmRNSSecond Price Monitoring Extn
30th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSPhase II Registration Study of HMPL-689 Initiated
28th Apr 20212:20 pmRNSResult of AGM
23rd Apr 20217:00 amRNSVesting of awards under Long Term Incentive Plan
14th Apr 202110:30 amRNSNotification of Dilution of Voting Rights
8th Apr 20218:30 amRNS$100m Investment by Baring Private Equity Asia
31st Mar 20217:00 amRNSTotal Voting Rights
29th Mar 20219:30 amRNSGrant of LTIP Awards and Share Options
29th Mar 20217:00 amRNSInitiates International Phase I Trials of HMPL-306
26th Mar 20217:00 amRNSAnnual Financial Report
24th Mar 20211:30 pmRNSAgreement to Divest Non-Core OTC Joint Venture
24th Mar 20217:00 amRNSPhase Ib/II Trial of Surufatinib with Tislelizumab
10th Mar 20217:00 amRNSVesting of awards under Long Term Incentive Plan
4th Mar 20213:15 pmRNSPublication of Form 20-F
4th Mar 202112:00 pmRNSFinal Results, Business Update and Name Change
3rd Feb 20217:00 amRNSNotice of Results
14th Jan 202110:00 amRNSSavolitinib Data to be Presented at Virtual WCLC
11th Jan 20217:00 amRNSChi-Med & Inmagene Announce Strategic Partnership
31st Dec 20207:00 amRNSBlocklisting Six Monthly Return
31st Dec 20207:00 amRNSTotal Voting Rights
30th Dec 202012:00 pmRNSNMPA approval of Surufatinib in China for ep-NET
29th Dec 20207:45 amRNSUS NDA Rolling Submission of Surufatinib Initiated
22nd Dec 20207:00 amRNSChi-Med to Present at JPM
15th Dec 20209:45 amRNSGrant of Share Options under Share Option Scheme
30th Nov 20207:00 amRNSTotal Voting Rights
27th Nov 20207:00 amRNSNotification of Dilution of Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.